

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.nspto.gov

APPLICATION NO. FILING DA	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/935,344 08/23/200	Vic Jira	115091.00101	115091.00101 8106	
27557 7590 07	/2003			
BLANK ROME COMISKY & MCCAULEY, LLP		EXAMINER		
900 17TH STREET, N.W., SI WASHINGTON, DC 20006	STREET, N.W., SUITE 1000 GTON, DC 20006		LUCAS, ZACHARIAH	
		ART UNIT	PAPER NUMBER	
		1648	~	
		DATE MAILED: 07/02/2003	5	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
•	09/935,344	JIRA ET AL.		
Office Action Summary	Examiner	Art Unit		
	Zachariah Lucas	1648		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with th	correspondenc address		
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) day ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDON	imely filed ys will be considered timely. in the mailing date of this communication. ED (35 U.S.C. § 133).		
1) Responsive to communication(s) filed on 23 A	<u> August 2001</u> .			
2a)☐ This action is FINAL . 2b)☐ Thi	is action is non-final.			
3) Since this application is in condition for allowa closed in accordance with the practice under the condition of Claims.	nce except for formal matters, p Ex parte Quayle, 1935 C.D. 11,	prosecution as to the merits is 453 O.G. 213.		
Disposition of Claims 4) Claim(s) 4.12 is/ore pending in the application				
 4)⊠ Claim(s) 1-12 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 				
5) Claim(s) is/are allowed.				
6) Claim(s) is/are rejected.				
7) Claim(s) is/are rejected.				
8) Claim(s) 1-12 are subject to restriction and/or e	election requirement.			
Application Papers	·			
9) The specification is objected to by the Examine	r.			
10)☐ The drawing(s) filed on is/are: a)☐ accep	oted or b) objected to by the Ex	aminer.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.				
12) The oath or declaration is objected to by the Ex	aminer.			
Priority under 35 U.S.C. §§ 119 and 120	•			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a)□ All b)□ Some * c)□ None of:				
1. Certified copies of the priority documents have been received.				
2. Certified copies of the priority documents have been received in Application No				
 3. Copies of the certified copies of the prior application from the International But * See the attached detailed Office action for a list 	reau (PCT Rule 17.2(a)).			
14) Acknowledgment is made of a claim for domestic	c priority under 35 U.S.C. § 119	(e) (to a provisional application).		
a) ☐ The translation of the foreign language pro 15)☐ Acknowledgment is made of a claim for domesti	• •	•		
Attachment(s)				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informa	ry (PTO-413) Paper No(s) I Patent Application (PTO-152)		

Application/Control Number: 09/935,344

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-9, drawn to antiviral vaccines comprising one or more heat-inactivated viral antigens, classified in class 424, subclass 204.1.
 - II. Claims 10-12, drawn to therapeutic compositions comprising a denatured pathogen antigen, and a denatured tissue from a pathogen infected host, classified in class 424, subclass 184.1.

For each of Groups I and II above, restriction to one of the following is also required under 35 USC 121. Therefore, election is required of one of Groups I or II, and to one of inventions identified below.

The Applicant is required to elect one of the viral pathogens listed in claims 2 or 4.

The inventions are distinct, each from the other because of the following reasons:

2. The various inventions listed in claims 2 and 4 are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately usable. See MPEP § 806.05(d). In the instant case, each of the subcombinations has separate utility. Each of them is independently usable as a composition for

Page 3

Application/Control Number: 09/935,344

Art Unit: 1648

the treatment of, or for inducing an immune reaction against, infection by a different viral pathogen.

3. Inventions II and I are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the combination does not rely on the particulars of the subcombination for patentability, but relies on the combination of the subcombination with another composition. The subcombination has the same separate utility as does the composition, the ability to act as a vaccine or therapeutic against pathogenic infections.

Conclusion

- 4. Because these inventions are distinct for the reasons given above, and because the literature and sequence searches required for any one of the groups is not required for the others, restriction for examination purposes as indicated is proper.
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/935,344

Art Unit: 1648

Any inquiry concerning this communication or earlier communications from the 6. examiner should be directed to Zachariah Lucas whose telephone number is 703-308-4240. The examiner can normally be reached on Monday-Friday, 8 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4027. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Patent Examiner June 26, 2003

TECHNOLOGY CENTER 1600